JPWO2020227097A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020227097A5
JPWO2020227097A5 JP2021564996A JP2021564996A JPWO2020227097A5 JP WO2020227097 A5 JPWO2020227097 A5 JP WO2020227097A5 JP 2021564996 A JP2021564996 A JP 2021564996A JP 2021564996 A JP2021564996 A JP 2021564996A JP WO2020227097 A5 JPWO2020227097 A5 JP WO2020227097A5
Authority
JP
Japan
Prior art keywords
alkyl
epilepsy
group
formula
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021564996A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530989A5 (https=
JP7671990B2 (ja
JP2022530989A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/031039 external-priority patent/WO2020227097A1/en
Publication of JP2022530989A publication Critical patent/JP2022530989A/ja
Publication of JPWO2020227097A5 publication Critical patent/JPWO2020227097A5/ja
Publication of JP2022530989A5 publication Critical patent/JP2022530989A5/ja
Application granted granted Critical
Publication of JP7671990B2 publication Critical patent/JP7671990B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021564996A 2019-05-03 2020-05-01 Kcnt1阻害剤および使用する方法 Active JP7671990B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962842861P 2019-05-03 2019-05-03
US201962842855P 2019-05-03 2019-05-03
US201962842858P 2019-05-03 2019-05-03
US62/842,858 2019-05-03
US62/842,861 2019-05-03
US62/842,855 2019-05-03
US202062982858P 2020-02-28 2020-02-28
US62/982,858 2020-02-28
PCT/US2020/031039 WO2020227097A1 (en) 2019-05-03 2020-05-01 Kcnt1 inhibitors and methods of use

Publications (4)

Publication Number Publication Date
JP2022530989A JP2022530989A (ja) 2022-07-05
JPWO2020227097A5 true JPWO2020227097A5 (https=) 2023-05-11
JP2022530989A5 JP2022530989A5 (https=) 2023-05-11
JP7671990B2 JP7671990B2 (ja) 2025-05-07

Family

ID=73050875

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021564996A Active JP7671990B2 (ja) 2019-05-03 2020-05-01 Kcnt1阻害剤および使用する方法

Country Status (17)

Country Link
US (1) US20220280476A1 (https=)
EP (2) EP3962479B1 (https=)
JP (1) JP7671990B2 (https=)
KR (2) KR20250172745A (https=)
CN (1) CN114206335B (https=)
AU (2) AU2020267355B2 (https=)
BR (1) BR112021022061A2 (https=)
CA (1) CA3139062A1 (https=)
CL (1) CL2021002876A1 (https=)
CO (1) CO2021016469A2 (https=)
EC (1) ECSP21087657A (https=)
IL (2) IL287751B2 (https=)
MX (1) MX2021013422A (https=)
PE (1) PE20220017A1 (https=)
SA (1) SA521430753B1 (https=)
SG (1) SG11202112212WA (https=)
WO (1) WO2020227097A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7066871B2 (ja) 2017-12-15 2022-05-13 シロニックス リニューアブルス,インコーポレイティド 界面活性剤を形成するための反応性蒸留
US10934266B2 (en) 2018-07-12 2021-03-02 Sironix Renewables, Inc. Surfactants from long-chain carbon-containing molecules
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
KR20250172745A (ko) * 2019-05-03 2025-12-09 프락시스 프리시젼 메디신즈, 인크. Kcnt1 억제제 및 사용 방법
JP7699836B2 (ja) 2020-02-28 2025-06-30 プラクシス プレシジョン メディシンズ, インコーポレイテッド Kcnt1阻害剤、および使用方法
EP4146151A4 (en) 2020-05-04 2024-12-11 Sironix Renewables, Inc. FURANIC SURFACTANT COMPOSITIONS AND METHODS
CA3188825A1 (en) * 2020-07-06 2022-01-13 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
WO2022140547A2 (en) * 2020-12-22 2022-06-30 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2022231872A1 (en) * 2021-04-29 2022-11-03 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
MX2024007031A (es) 2021-12-10 2024-11-08 Sironix Renewables Inc Ajustar sulfonacion y controlar composiciones surfactantes de oleo-furano
WO2023211855A1 (en) * 2022-04-25 2023-11-02 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising a thiophene core and methods of use
EP4630399A1 (en) * 2022-12-05 2025-10-15 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising a phenyl, pyridine, or pyrimidine core and methods of use
WO2025117662A1 (en) * 2023-11-29 2025-06-05 Actio Biosciences, Inc. Heterocyclic compounds useful as kcnt1 inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
DE19929076A1 (de) 1999-06-25 2000-12-28 Aventis Pharma Gmbh Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
AU5464901A (en) * 2000-03-01 2001-09-12 Nihon Bayer Agrochem K.K. Dichloropyridyl- and dichloroisothiazolyl-thiocarboxamides and their use as microbicides
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
WO2005066137A1 (en) * 2003-12-19 2005-07-21 Neurogen Corporation 2,5-diaryl-1h-imidazole-4-carboxamides as neurokinin-3 receptor modulators for the treatment of central nervous system and peripheral diseases
EP1838690A2 (en) 2004-12-21 2007-10-03 Devgen N.V. Compounds with kv4 ion channel activity
WO2018204765A1 (en) * 2017-05-05 2018-11-08 Pairnomix, Llc Methods of treating epilepsy and kcnq2 related conditions
US20200129538A1 (en) * 2017-06-13 2020-04-30 The Florey Institute Of Neuroscience And Mental Health Compositions and methods for treating conditions associated with gain-of-function mutations in kcnt1
BR112020014428A2 (pt) * 2018-01-19 2020-12-01 Cytokinetics, Inc. composto, composição farmacêutica, e, métodos para o tratamento de uma doença cardíaca em um indivíduo, para o tratamento de uma doença ou condição que está associada com cavidade ventricular esquerda pequena e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia do miocárdio ou fibrose cardíaca, para o tratamento de uma doença ou condição selecionada dentre distrofias musculares e doenças de armazenamento do glicogênio e para inibição do sarcômero cardíaco
CN108517358A (zh) * 2018-04-09 2018-09-11 重庆医科大学附属第医院 一种辅助癫痫诊断的标志物及其检测试剂盒
KR20250172745A (ko) * 2019-05-03 2025-12-09 프락시스 프리시젼 메디신즈, 인크. Kcnt1 억제제 및 사용 방법
KR20220016086A (ko) * 2019-05-03 2022-02-08 프락시스 프리시젼 메디신즈, 인크. Kcnt1 억제제 및 사용 방법
US11767325B2 (en) * 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
JP7699836B2 (ja) * 2020-02-28 2025-06-30 プラクシス プレシジョン メディシンズ, インコーポレイテッド Kcnt1阻害剤、および使用方法
KR20230005168A (ko) * 2020-03-23 2023-01-09 프락시스 프리시젼 메디신즈, 인크. Kcnt1 억제제 및 사용 방법
CA3188825A1 (en) * 2020-07-06 2022-01-13 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
US11773088B2 (en) * 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
WO2022140547A2 (en) * 2020-12-22 2022-06-30 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use

Similar Documents

Publication Publication Date Title
JPWO2020227097A5 (https=)
JP5733982B2 (ja) サイトカインの産生を抑制する化合物及びその調製方法
TW202409017A (zh) 雜環類化合物、其製備方法及其在醫藥上的應用
ES2527418T3 (es) Derivados de piridinona novedosos y su uso como moduladores alostéricos positivos de receptores mGluR2
US5716955A (en) Substituted imidazole compounds
US8148408B2 (en) Selective substituted pyridine ligands for neuronal nicotinic receptors
AU2003303484B2 (en) Quinazolinones as potassium channel modulators
PT1864975E (pt) Derivados de nicotinamida úteis como inibidores de p38
JP2019519583A (ja) 神経性疾患および神経変性疾患を処置するための5,7−ジヒドロピロロピリジン誘導体
JP2011500815A5 (https=)
JP2006513268A5 (ja) アンタゴニスト活性を有するベンゾアゾリルピペラジン誘導体
JP2006506462A5 (https=)
KR20210049858A (ko) Jak 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리딘 화합물 및 이의 용도
EP2231652B1 (de) Neue 2-hetarylthiazol-4-carbonsäureamid-derivate, deren herstellung und verwendung als arzneimittel
JPS637545B2 (https=)
JP2008513413A5 (https=)
JP2006508107A5 (https=)
JP2006502143A5 (https=)
EP2956135B1 (en) Heterocyclic amide derivatives as p2x7 receptor antagonists
CA2378241A1 (en) Benzanilides as potassium channel openers
JP2003506387A5 (https=)
EP2099300A1 (en) Il-8 receptor antagonists
EP2070916A1 (de) 2-Aryl-thiazol-4-carbonsäureamid-Derivate, deren Herstellung und Verwendung als Arzneimittel
JPH0649688B2 (ja) ピリミジン誘導体、その製造法およびその医薬組成物
JP2024160326A (ja) Eaat2活性化因子およびその使用方法